Among intensive care unit (ICU) patients with hypovolemia, treatment with colloids vs crystalloids was associated with similar 28-day mortality, according to a multicenter, randomized clinical trial ...

Centhaquine, a new drug to treat patients who have severe blood or fluid loss, significantly improved outcomes and reduced death rate among shock patients. Centhaquine significantly improved survival ...

KANSAS CITY, Mo.--(BUSINESS WIRE)--Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic ...

Intravenous administration of isotonic fluids is the standard emergency treatment in the U.S. for patients with severe blood loss, but UC San Diego bioengineering researchers have reported improved ...

Septic shock results in approximately 350,000 deaths in the U.S. each year, the leading cause of hospital-related mortality and a major financial burden for the medical system Absolute hypovolemia ...

Dr Reddy's and Pharmazz are collaborating to roll out Centhaquine, a revolutionary resuscitative agent for hypovolemic shock in India. The drug aims to improve cardiac output and blood circulation, ...

Drugmaker Dr. Reddy’s Laboratories has signed a licensing agreement to market U.S. biopharmaceutical company Pharmazz’s Centhaquine, a ‘first-of-its-kind’ resuscitative agent to treat hypovolemic ...

Septic shock results in approximately 350,000 deaths in the U.S. each year, the leading cause of hospital-related mortality and a major financial burden for the medical system Six trial sites with ...